Dr. David-Alexandre TREGOUET, ELEANOR Director
Pr. Stéphanie DEBETTE, ELEANOR Deputy Director
Dr. David-Alexandre TREGOUET, ELEANOR Director
Pr. Stéphanie DEBETTE, ELEANOR Deputy Director
The purpose of our research is to identify groups of individuals who are at high risk of developing three common and tightly linked neurological and vascular conditions, dementia, stroke and venous thrombosis, to discover novel etiological factors and therapeutic targets, and to propose more personalized preventive strategies through improved risk stratification.
Our research program relies on major components: (i) large-scale epidemiological and clinical cohorts coupled with biosamples; (ii) the deployment of cutting-edge high-throughput technologies for deep molecular phenotyping; (iii) the application of advanced statistical methodologies; (iv) a group of experts in molecular-clinical epidemiology and (v) a widespread network of collaborators that enables us to contribute to the functional characterization of the identified biomarkers.
Our project is focusing on three inter-related clinical outcomes, cognitive impairment / dementia, stroke, and thrombosis and is organized around 4 themes:
Molecular epidemiology of vascular brain aging, (PI: Stéphanie Debette)
Using collaborative genome-wide association study meta-analyses and next generation sequencing data we are studying the genetic underpinnings of stroke and MRI-markers of covert cerebral small vessel disease (SVD). We have a growing interest in cross-ancestry studies, as these are crucial to enhance genomic discovery and make results more representative. Through the ERC SEGWAY we are taking a lifespan approach to explore early determinants of brain aging and the impact of genes predisposing to stroke, dementia and SVD on brain microstructure in young adults (i-Share cohort). In the RHU SHIVA project (national investment for the future funding), following up on efforts that we initiated in the EU-JPND BRIDGET program, we are now expanding our explorations to other omics approaches (epigenomics, transcriptomics, proteomics and metabolomics), focusing in particular on deciphering the molecular underpinnings of covert SVD and its contribution to stroke and dementia. Finally, we are engaged in leveraging these molecular epidemiology studies to accelerate drug discovery and improve risk prediction/stratification for targeted prevention. Our group is also involved in European therapeutic guideline coordination.
Exposome of brain aging and dementia (PI: Cécilia Samieri)
The network and dynamics of environmental factors leading to age-related brain diseases has yet to be elucidated, in order to identify the most impactful targets for prevention. This exposome research axis leverages molecular epidemiology, brain imaging and advanced statistical approaches deployed to population-based cohorts with biobanks in order to investigate: (1) the exposome of brain health at key ages, and (2) the underlying pathways and life-course dynamics. The general aims are to: refine assessment of already-known exposures (eg, diet biomarkers); explore novel exposures (eg, chemical mixtures); investigate beyond individual exposures (eg, microbiome interactions); and eventually model the global exposome network, to improve etiological modeling of age-related brain diseases. We will capitalize on existing data (e.g. the 3C cohort) and target younger populations, building a new population-based cohort of 2000 participants aged 55-80 years from the community living in Bordeaux metropole, the B cube (Biobank and Brain Health in Bordeaux) study.
Precision Medicine for better prophylaxis & better knowledge in venous thrombosis (PI: David-Alexandre Trégouët)
After spending several years to identify common genetic factors for venous thrombosis (VT) in the general population, we are now embarking into a more integrative analysis of various molecular determinants (genes; epigenetic marks, proteins,…) on specific subgroups of individuals at higher risk of VT including women under oral contraceptives, patients with a previous history of VT and patients with viral infections.
In parallel, building on our recent successes, we will continue our genetic investigations of rare forms of unexplained inherited VT through the application of whole exome/genome sequencing in familial cases.
Integrative approach for vascular and brain disorders (all PIs)
The deep characterization and understanding of the biology of a complex disease requires to integrate results/data from others diseases as they very often share common risk factors and pathophysiological mechanisms. By capitalizing on the existence of complementary and synergistic expertise and bioresources brought by ELEANOR’s PIs in different but interrelated diseases, we are implementing an integrative research strategy to optimize the identification and the characterization of molecular determinants associated with some of the most common age-related diseases.
Sargurupremraj M, Suzuki H, Jian X, Sarnowski C, Evans TE, Bis JC, Eiriksdottir G, Sakaue S, Terzikhan N, Habes M, Zhao W, Armstrong NJ, Hofer E, Yanek LR, Hagenaars SP, Kumar RB, van den Akker EB, McWhirter RE, Trompet S, Mishra A, Saba Y, Satizabal CL, Beaudet G, Petit L, Tsuchida A, Zago L, Schilling S, Sigurdsson S, Gottesman RF, Lewis CE, Aggarwal NT, Lopez OL, Smith JA, Valdes Hernandez MC, van der Grond J, Wright MJ, Knol MJ, Dorr M, Thomson RJ, Bordes C, Le Grand Q, Duperron MG, Smith AV, Knopman DS, Schreiner PJ, Evans DA, Rotter JI, Beiser AS, Maniega SM, Beekman M, Trollor J, Stott DJ, Vernooij MW, Wittfeld K, Niessen WJ, Soumare A, Boerwinkle E, Sidney S, Turner ST, Davies G, Thalamuthu A, Volker U, van Buchem MA, Bryan RN, Dupuis J, Bastin ME, Ames D, Teumer A, Amouyel P, Kwok JB, Bulow R, Deary IJ, Schofield PR, Brodaty H, Jiang J, Tabara Y, Setoh K, Miyamoto S, Yoshida K, Nagata M, Kamatani Y, Matsuda F, Psaty BM, Bennett DA, De Jager PL, Mosley TH, Sachdev PS, Schmidt R, Warren HR, Evangelou E, Tregouet DA, International Network against Thrombosis C, International Headache Genomics C, Ikram MA, Wen W, DeCarli C, Srikanth VK, Jukema JW, Slagboom EP, Kardia SLR, Okada Y, Mazoyer B, Wardlaw JM, Nyquist PA, Mather KA, Grabe HJ, Schmidt H, Van Duijn CM, Gudnason V, Longstreth WT, Jr., Launer LJ, Lathrop M, Seshadri S, Tzourio C, Adams HH, Matthews PM, Fornage M, Debette S. Cerebral small vessel disease genomics and its implications across the lifespan. Nat Commun. 2020 Dec 8;11(1):6285. https://doi.org/10.1038/s41467-020-19111-2
Goumidi L, Thibord F, Wiggins KL, Li-Gao R, Brown MR, van Hylckama Vlieg A, Souto JC, Soria JM, Ibrahim-Kosta M, Saut N, Daian D, Olaso R, Amouyel P, Debette S, Boland A, Bailly P, Morrison AC, Mook-Kanamori DO, Deleuze JF, Johnson A, de Vries PS, Sabater-Lleal M, Chiaroni J, Smith NL, Rosendaal FR, Chasman DI, Tregouet DA, Morange PE. Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. Blood. 2021 Apr 29;137(17):2394-402. https://doi.org/10.1182/blood.2020008997
Harris WS, Tintle NL, Imamura F, Qian F, Korat AVA, Marklund M, Djousse L, Bassett JK, Carmichael P-H, Chen Y-Y, Hirakawa Y, Kupers LK, Laguzzi F, Lankinen M, Murphy RA, Samieri C, Senn MK, Shi P, Virtanen JK, Brouwer IA, Chien K-L, Eiriksdottir G, Forouhi NG, Geleijnse JM, Giles GG, Gudnason V, Helmer C, Hodge A, Jackson R, Khaw K-T, Laakso M, Lai H, Laurin D, Leander K, Lindsay J, Micha R, Mursu J, Ninomiya T, Post W, Psaty BM, Riserus U, Robinson JG, Shadyab AH, Snetselaar L, Sala-Vila A, Sun Y, Steffen LM, Tsai MY, Wareham NJ, Wood AC, Wu JHY, Hu F, Sun Q, Siscovick DS, Lemaitre RN, Mozaffarian D. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nat Commun. 2021 Apr 22;12(1):2329. https://doi.org/10.1038/s41467-021-22370-2
Le Grand Q, Satizabal CL, Sargurupremraj M, Mishra A, Soumare A, Laurent A, Crivello F, Tsuchida A, Shin J, Macalli M, Singh B, Beiser AS, DeCarli C, Fletcher E, Paus T, Lathrop M, Adams HHH, Bis JC, Seshadri S, Tzourio C, Mazoyer B, Debette S. Genomic Studies Across the Lifespan Point to Early Mechanisms Determining Subcortical Volumes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Oct 23. https://doi.org/10.1016/j.bpsc.2021.10.011
Lefevre-Arbogast S, Hejblum BP, Helmer C, Klose C, Manach C, Low DY, Urpi-Sarda M, Andres-Lacueva C, Gonzalez-Dominguez R, Aigner L, Altendorfer B, Lucassen PJ, Ruigrok SR, De Lucia C, Du Preez A, Proust-Lima C, Thuret S, Korosi A, Samieri C. Early signature in the blood lipidome associated with subsequent cognitive decline in the elderly: A case-control analysis nested within the Three-City cohort study. EBioMedicine. 2021 Feb;64:103216. https://doi.org/10.1016/j.ebiom.2021.103216
Morange PE, Peiretti F, Gourhant L, Proust C, Soukarieh O, Pulcrano-Nicolas AS, Saripella GV, Stefanucci L, Lacroix R, Ibrahim-Kosta M, Lemarie CA, Frontini M, Alessi MC, Tregouet DA, Couturaud F. A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. PLoS Genet. 2021 Jan 19;17(1):e1009284. https://doi.org/10.1371/journal.pgen.1009284
Razzaq M, Iglesias MJ, Ibrahim-Kosta M, Goumidi L, Soukarieh O, Proust C, Roux M, Suchon P, Boland A, Daiain D, Olaso R, Havervall S, Thalin C, Butler L, Deleuze JF, Odeberg J, Morange PE, Tregouet DA. An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism. Sci Rep. 2021 Jul 7;11(1):14015. https://doi.org/10.1038/s41598-021-93390-7
Samieri C, Yassine HN, Melo van Lent D, Lefevre-Arbogast S, van de Rest O, Bowman GL, Scarmeas N. Personalized nutrition for dementia prevention. Alzheimers Dement. 2021 Nov 10. https://doi.org/10.1002/alz.12486
Thomas A, Crivello F, Mazoyer B, Debette S, Tzourio C, Samieri C. Fish Intake and MRI Burden of Cerebrovascular Disease in Older Adults. Neurology. 2021 Nov 30;97(22):e2213-e22. https://doi.org/10.1212/WNL.0000000000012916
Bordes C, Sargurupremraj M, Mishra A, Debette S. Genetics of common cerebral small vessel disease. Nat Rev Neurol. 2022 Feb;18(2):84-101. https://doi.org/10.1038/s41582-021-00592-8
Mishra A, Duplaa C, Vojinovic D, Suzuki H, Sargurupremraj M, Zilhao NR, Li S, Bartz TM, Jian X, Zhao W, Hofer E, Wittfeld K, Harris SE, van der Auwera-Palitschka S, Luciano M, Bis JC, Adams HHH, Satizabal CL, Gottesman RF, Gampawar PG, Bulow R, Weiss S, Yu M, Bastin ME, Lopez OL, Vernooij MW, Beiser AS, Volker U, Kacprowski T, Soumare A, Smith JA, Knopman DS, Morris Z, Zhu Y, Rotter JI, Dufouil C, Valdes Hernandez M, Munoz Maniega S, Lathrop M, Boerwinkle E, Schmidt R, Ihara M, Mazoyer B, Yang Q, Joutel A, Tournier-Lasserve E, Launer LJ, Deary IJ, Mosley TH, Amouyel P, DeCarli CS, Psaty BM, Tzourio C, Kardia SLR, Grabe HJ, Teumer A, van Duijn CM, Schmidt H, Wardlaw JM, Ikram MA, Fornage M, Gudnason V, Seshadri S, Matthews PM, Longstreth WT, Couffinhal T, Debette S. Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate. Brain. 2022 May 2. https://doi.org/10.1093/brain/awab432
Details
Centre de recherche INSERM U1219
Université de Bordeaux, ISPED case 11
146 rue Léo-Saignat 33076 BORDEAUX cedex
Tél : +33 (0)5 57 57 16 59